| |
Pre COVID-19 (n = 614)
|
COVID-19 (n = 600)
|
p value
|
|---|
|
Symptomatic
|
103 (16.7)
|
58 (9.6)
|
0.003
|
|
Referral (n)
|
NA
|
58 (9.6)
| |
|
Deranged INR
|
195 (37.14)
|
204 (40.31)
|
0.30
|
|
Subtherapeutic
|
137 (26.1)
|
157 (31)
|
0.08
|
|
Supratherapeutic INR < 5
|
58 (11.04)
|
47 (9.2)
|
0.35
|
|
Supratherapeutic INR > 5
|
23 (4.3)
|
18 (3.5)
|
0.52
|
|
Clinical events
|
|
Hospitalization
|
29 (4.7)
|
19 (3.1)
|
0.18
|
|
Major bleeding
|
7 (1.1)
|
3 (0.5)
|
0.34
|
|
Minor bleeding
|
4 (0.6)
|
5 (0.8)
|
0.75
|
|
Thromboembolic episode
|
15 (2.4)
|
10 (1.6)
|
0.42
|
|
CVA/TIA
|
11 (1.7)
|
7 (1.1)
|
0.77
|
|
Prosthetic valve thrombosis
|
4 (0.6)
|
3 (0.5)
|
1.00
|
- INR international normalized ratio, CVA cerebrovascular accident, TIA transient ischemic attack
